Randomized Study of Peginterferon-α2a Plus Ribavirin vs Peginterferon-α2b Plus Ribavirin in Chronic Hepatitis CMaria Grazia Rumi, Massimo Colombo, R. Soffredini et al.|Gastroenterology|2009Cited by 199
Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV InfectionElisabetta Degasperi, Pietro Lampertico, R. Soffredini et al.|Clinical Gastroenterology and Hepatology|2018Cited by 114
Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis CAlessio Aghemo, Massimo Colombo, R. Soffredini et al.|Hepatology|2012Cited by 94
Interleukin 28B Polymorphism Predicts Pegylated Interferon Plus Ribavirin Treatment Outcome in Chronic Hepatitis C Genotype 4Stella De Nicola, Massimo Colombo, Alessio Aghemo et al.|Hepatology|2011Cited by 83
Incidence of liver- and non-liver-related outcomes in patients with HCV-cirrhosis after SVRRoberta D’Ambrosio, Pietro Lampertico, R. Soffredini et al.|Journal of Hepatology|2021Cited by 75